Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] SK hynix(000660) – Decision on Cash and In-Kind Dividend / 2024-01-25

Posted on January 25, 2024July 29, 2026 By K-STOCK Editor No Comments on [Disclosure] SK hynix(000660) – Decision on Cash and In-Kind Dividend / 2024-01-25

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

SK hynix has resolved to pay a year-end cash dividend of KRW 300 per common share for FY2023, with the total dividend payout amounting to approximately KRW 206.4 billion.

📊 [Key Disclosure Details & Financial Summary]

  • Dividend Overview
    • Dividend Classification: Year-End Dividend
    • Dividend Type: Cash Dividend
    • Differential Dividend: N/A
  • Dividend per Share & Total Amount
    • Dividend per Common Share: KRW 300
    • Total Dividend Amount: KRW 206.44B (KRW 206,441,594,700)
    • Dividend Yield: Common stock 0.2% (based on arithmetic average of closing prices for 1 week prior to 2 trading days before the record date)
  • Record Date & Schedule
    • Dividend Record Date: December 31, 2023
    • Scheduled Dividend Payment Date: To be paid within 1 month from the AGM resolution date
    • General Shareholders’ Meeting: To be convened
  • Board Resolution Details
    • Board Resolution Date: January 24, 2024 (7 Independent Directors attended, 0 absent)

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Final Dividend Approval at AGM and Payment Schedule Verification

This year-end dividend proposal has been approved by the Board of Directors and is subject to final approval at the upcoming Annual General Meeting. Verifying whether the proposal is passed without changes at the AGM and confirming the finalized payment date is crucial for tracking shareholder return execution. Details can be verified in future ‘Decision on Calling of General Shareholders’ Meeting’ and ‘Results of General Shareholders’ Meeting’ disclosures.

📢 Disclaimer & Fact Source

Source: This content was newly generated and structured based on official disclosure data from the Financial Supervisory Service’s DART system.

Investment Risk Warning: This content is provided solely for information purposes and linguistic reference. Under no circumstances does it constitute financial advice or a recommendation to buy/sell specific stocks. All investment decisions and financial responsibilities lie entirely with the investor.

Contact Us: For compliance queries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Semiconductors

Post navigation

Previous Post: [Disclosure] SK hynix(000660) – Change in Revenue or Loss/Profit Structure Exceeding 30% (15% for Large Corporations) / 2024-01-25
Next Post: [Disclosure] HPSP (403870) – Additional Listing (Exercise of Stock Options) / 2024-01-29

Related Posts

[Disclosure] Hanwha Ocean (042660) – Signing of Single Sales/Supply Contract / 2025-03-17 Disclosures
[Disclosure] ALTEOGEN (196170) – Execution of Exclusive License Agreement (ALT-B4 Technology) / 2024-11-08 Disclosures
[Disclosure] Jusung Engineering (036930) – Withdrawal of Decision on Corporate Spin-off / 2024-10-29 Disclosures
[Disclosure] Hanwha Systems (272210) – Corrected Filing for Subsidiary Hanwha Philly Shipyard Inc. Capital Increase (Payment Date Revised to Dec 23, 2025) Disclosures
[Disclosure] ALTEOGEN (196170) – Investor Relations (IR) Host / 2026-01-08 Disclosures
[Disclosure] Samsung Biologics (207940) – Decision on Calling of General Shareholders Meeting / 2026-02-11 Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme